Skip to main content
    C

    CervoMed Inc. (CRVO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.25
    -0.04 (-1.75%)

    Market Cap: $34.62M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    26%(9/34)
    Avg Surprise
    -5922.65%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.57
    Range$-0.73 - $-0.44
    4 analysts
    EPS RevisionsNo revisions (7d)
    3
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.58+3.0%
    60d ago$-0.62+8.5%
    30d ago$-0.570.0%
    7d ago$-0.570.0%
    Current$-0.57
    Revenue Consensus
    $50000
    Range$0 - $300000
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.02
    Range$-0.75 - $1.06
    5 analysts
    Revenue Consensus
    $-29170
    Range$-162500 - $637500
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.02---
    Sep 26EST
    		-$-0.57---
    Jun 26
    Reported Aug 7
    		$-0.64$-0.87+26.44%Beat+8.6%
    Mar 26
    Reported May 18
    		$-0.86$-0.79-8.46%Miss-53.6%
    Dec 25
    Reported Mar 13
    		$-0.88$-0.70-25.71%Miss-10.0%
    Sep 25
    Reported Nov 7
    		$-0.84$-0.64-31.25%Miss-52.7%
    Jun 25
    Reported Aug 8
    		$-0.70$-0.62-12.90%Miss-159.3%
    Mar 25
    Reported May 12
    		$-0.56$-0.62+10.16%Beat-36.6%
    Dec 24
    Reported Mar 17
    		$-0.80$-0.63-26.98%Miss-110.5%
    Sep 24
    Reported Nov 12
    		$-0.55$-0.41-34.15%Miss-184.6%
    Jun 24
    Reported Aug 9
    		$-0.27$-0.29+6.90%Beat+82.6%
    Mar 24
    Reported May 14
    		$-0.41$-0.32-28.13%Miss+79.6%
    Dec 23
    Reported Mar 25
    		$-0.38$-0.29-31.03%Miss+81.0%
    Sep 23
    Reported Nov 13
    		$0.65$-0.95+168.42%Beat+131.6%
    Jun 23
    Reported Aug 8
    		$-1.55$-2.90+46.42%Beat+49.7%
    Mar 23
    Reported May 15
    		$-2.01$-1.91-5.24%Miss+39.6%
    Dec 22
    Reported Mar 21
    		$-2.00$-2.22+9.91%Beat+11.1%
    Sep 22
    Reported Nov 14
    		$-2.06$-2.06+0.00%Beat+77.1%
    Jun 22
    Reported Sep 28
    		$-3.09$-2.04-51.47%Miss-3.0%
    Mar 22
    Reported Jun 28
    		$-3.33$-1.75-90.29%Miss+26.0%
    Dec 21
    Reported Mar 29
    		$-2.25$-0.04-5525.00%Miss+50.0%
    Sep 21
    Reported Dec 29
    		$-9.00$-0.04-22400.00%Miss-71.4%
    Jun 21
    Reported Sep 28
    		$-3.00$-0.04-6566.67%Miss+60.0%
    Mar 21
    Reported May 7
    		$-4.50$-0.04-9900.00%Miss+14.3%
    Dec 20
    Reported Mar 31
    		$-4.50$-0.06-8081.82%Miss-121.4%
    Sep 20
    Reported Nov 12
    		$-5.25$-0.06-9445.45%Miss+88.3%
    Jun 20
    Reported Aug 10
    		$-7.50$-0.06-12400.00%Miss+84.1%
    Mar 20
    Reported May 11
    		$-5.25$-0.09-5733.33%Miss+91.4%
    Dec 19
    Reported Mar 17
    		$21.00$-0.14+15100.00%Beat+116.9%
    Sep 19
    Reported Nov 11
    		$-45.00$-0.71-6238.03%Miss+69.2%
    Jun 19
    Reported Aug 8
    		$-47.25$-0.90-5150.00%Miss+16.0%
    Mar 19
    Reported May 9
    		$-60.75$-0.91-6575.82%Miss-16086.8%
    Dec 18
    Reported Mar 31
    		$-124.50$-1.28-9626.56%Miss-62350.0%
    Sep 18
    Reported Dec 29
    		$-146.25$-0.90-16150.00%Miss-26983.3%
    Jun 18
    Reported Aug 13
    		$-56.25$-0.06-93650.00%Miss-3078.0%
    Mar 18
    Reported Apr 3
    		$0.38$-0.04+1050.00%Beat-
    Sep 17
    Reported Dec 29
    		$0.20$0.00N/ABeat-
    Jun 17
    Reported Aug 21
    		$-0.54$0.00N/AMiss-
    Mar 17
    Reported May 15
    		$-1.77$0.00N/AMiss-
    Dec 16
    Reported Mar 31
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.70EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-9407.00%
    ROE-107.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio8.57xQuick Ratio8.57x
    Trading Statistics
    Beta-4.30Avg Volume302.28K
    52-Week High$10.0052-Week Low$2.13

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.87
    SMA 20$2.75
    SMA 50$2.69
    SMA 200$3.81
    EMA 10$2.66
    EMA 20$2.72
    EMA 50$2.76
    EMA 200$3.97

    MACD

    Line: -0.04Signal: 0.05Hist: -0.09

    ADX

    ADX: 28.6+DI: 19.3-DI: 30.7

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down96.0
    PSAR$3.30

    Bollinger Bands

    Upper Band$3.51
    Lower Band$2.00
    %B Position5473%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    35.6

    Momentum Oscillators

    Stoch %K9.7
    Stoch %D17.0
    Williams %R-90.8
    ROC (10d)-23.2%
    Momentum-0.68
    CCI (20d)-104.4
    MFI (14d)57.8

    Volatility Measures

    ATR (14d)$0.23(10.2%)
    StdDev (20d)0.38
    Hist Vol107.2%(High)

    Volume Flow

    VWAP$2.26
    OBV281.5M
    AD Line-174.4M
    CMF (20d)0.061

    Volume Metrics

    Avg Vol (20d)321.5K
    Vol Ratio0.6x
    VWMA (20d)$2.79

    Pivot Points

    R3$2.70
    R2$2.56
    R1$2.42
    Pivot Point$2.28
    S1$2.14
    S2$2.00
    S3$1.86

    Advanced Oscillators

    TSI-4.22
    Ultimate Osc38.9
    KST111.62

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$8,726$322,569$1.76M$1.92M$2.16M$1.94M$3.29M$2.35M$2.49M$1.53M
    Cost of Revenue$0$0N/A$0$0$0$7.09M$0$0$0$2.85M$0
    Gross Profit$0$0$8,726$322,569$1.76M$1.92M$2.16M$1.94M$3.29M$2.35M$2.49M$1.53M
    Operating Expenses$6.68M$8.11M$8.34M$8.37M$8.37M$7.22M$9.40M$7.34M$6.28M$4.94M$4.97M$4.20M
    R&D$4.32M$5.14M$5.83M$6.04M$5.11M$4.84M$7.09M$5.13M$3.77M$2.81M$2.86M$1.79M
    SG&A$2.36M$2.98M$2.51M$2.33M$3.27M$2.38M$2.32M$2.21M$2.51M$2.13M$2.12M$2.41M
    Operating Income$-6,678,551$-8,110,524$-8,331,519$-8,044,199$-6,616,275$-5,302,884$-7,240,821$-5,396,273$-2,995,099$-2,594,938$-2,480,450$-2,675,129
    Interest Income$104,897$147,387$240,938$318,787$368,127$408,985$532,181$646,172$678,441$80,633$118,652$47,667
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-6,571,656$-7,964,158$-8,087,290$-7,726,639$-6,258,404$-4,894,034$-6,705,914$-4,753,541$-2,316,905$-2,514,335$-2,362,398$2.15M
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,571,656$-7,964,158$-8,087,290$-7,726,639$-6,258,404$-4,894,034$-6,705,914$-4,753,541$-2,316,905$-2,514,335$-2,362,398$2.15M
    EBITDA$-6,695,692$-8,181,649$-8,474,286$-8,266,951$-6,861,197$-5,554,847$-7,621,094$-5,883,703$-2,995,346$-2,594,968$-2,481,050$2.10M
    EBIT$-6,676,553$-8,111,545$-8,328,228$-8,045,426$-6,626,531$-5,303,019$-7,238,095$-5,399,713$-2,995,346$-2,594,968$-2,481,050$2.10M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRVO

    News

    CervoMed posts investor presentation disclosure; info added to website

    CervoMed (CRVO) has made an investor presentation available on its website under Regulation FD, covering its business, clinical studies, development plans...

    TradingView•10/14/26•Neutral

    CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

    CervoMed announced initial positive results from its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The study showed a reduction in mean plasma neurofilament light...

    Yahoo Finance•10/13/26•Bullish

    CervoMed Shows Progress in Treating Rare Aphasia Condition

    CervoMed (NASDAQ: CRVO) reported early positive results from its Phase 2a clinical study for neflamapimod in treating nonfluent variant primary progressive aphasia (nfvPPA). The 12-week data showed a significant...

    Benzinga•10/12/26•Bearish

    CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

    CervoMed Inc. announced initial positive results from its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The study showed a reduction in plasma neurofilament light...

    The Manila Times•10/12/26•Bullish

    A rare dementia can take away speech; no drug is approved for it. CervoMed saw a nerve-damage marker fall over 12 weeks.

    CervoMed (NASDAQ: CRVO) announced initial positive Phase 2a results for neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA)...

    Stock Titan•10/12/26•Bullish

    CRVO Valuation and Fair Value

    P/E
    -0.7x
    P/B
    1.0x
    See GNG's fair value

    CRVO Profitability: Margins, ROIC and FCF

    Operating margin
    -9407.0%
    Net margin
    0.0%
    ROE
    -107.6%
    FCF margin
    -8444.9%

    CRVO Competitors

    CompanyTicker
    Genenta Science SpA ADRGNTA
    CryoCell International IncCCEL
    Mural Oncology plcMURA
    NanoViricides IncNNVC
    Lite Strategy, Inc.LITS
    Elutia Inc.ELUT
    Edesa Biotech IncEDSA
    China Pharma Holdings IncCPHI

    Sector: Healthcare

    CRVO Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    0
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CRVO Bull Case vs Bear Case

    Bull case

    • 100.0% of CRVO's analyst ratings are Buy or Strong Buy.

    Bear case

    • CRVO beat EPS estimates in 25.0% of its last 8 reported quarters.
    • CRVO's quarterly revenue changed -99.6% year over year.

    CRVO Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -12.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.57
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 1 down

    Frequently Asked Questions About CRVO

    Does CRVO pay dividends?

    CervoMed Inc. (CRVO) does not currently pay a regular dividend.

    What is CRVO's market cap?

    CervoMed Inc. (CRVO) has a market capitalization of $34.62M with a current stock price of $2.25.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In